Standard chemotherapy represents the mainstay of treatment for the majority of CRC patients, either in resected stage II or III [37], and also for stage IV where polychemotherapy with 5-fluorouracil (5FU) and irinotecan, oxaliplatin, or both [38] is widely used in combination with either anti-VEGF or anti-EGFR drugs. The gene discussed is EGFR; the disease is colorectal carcinoma.